What are the recommended outpatient antibiotic regimens for an otherwise healthy adult with low‑risk community‑acquired pneumonia according to the 2026 guidelines?

Low-Risk Community-Acquired Pneumonia: Outpatient Antibiotic Regimens

First-Line Therapy for Previously Healthy Adults

Amoxicillin 1 gram orally three times daily for 5–7 days is the preferred first-line antibiotic for otherwise healthy adults with low-risk community-acquired pneumonia. 1, 2

• Amoxicillin provides activity against 90–95% of Streptococcus pneumoniae strains, including many penicillin-resistant isolates, making it the most effective oral agent for the predominant bacterial pathogen in CAP 1, 2
• This regimen carries a strong recommendation with moderate-quality evidence from the American Thoracic Society and Infectious Diseases Society of America 1, 2
• European respiratory societies and the CDC endorse amoxicillin as the standard empirical outpatient therapy for previously healthy adults 1, 2

Acceptable Alternatives

• Doxycycline 100 mg orally twice daily for 5–7 days serves as an acceptable alternative when amoxicillin is contraindicated, providing coverage of typical and atypical pathogens 1, 2, 3
• This carries a conditional recommendation with low-quality evidence 1, 2

Macrolide Monotherapy: Use Only When Local Resistance Is Low

• Macrolides (azithromycin 500 mg day 1, then 250 mg daily; or clarithromycin 500 mg twice daily) should only be used when local pneumococcal macrolide resistance is documented to be <25% 1, 2
• In most U.S. regions, macrolide resistance among S. pneumoniae ranges from 20–30%, making macrolide monotherapy unsafe as first-line therapy 1, 2
• Macrolide-resistant strains are associated with breakthrough pneumococcal bacteremia and treatment failure 1, 2

---

Treatment for Patients with Comorbidities or Recent Antibiotic Use

For adults with comorbidities (COPD, diabetes, chronic heart/lung/liver/renal disease, alcoholism, malignancy) or antibiotic use within the past 90 days, combination therapy is required rather than monotherapy. 1, 2, 3

Recommended Combination Regimens

Option 1: β-lactam plus macrolide or doxycycline

• Amoxicillin-clavulanate 875 mg/125 mg orally twice daily PLUS azithromycin (500 mg day 1, then 250 mg daily for days 2–5) 1, 2
• Alternative β-lactams: cefpodoxime or cefuroxime, each combined with a macrolide or doxycycline 100 mg twice daily 1, 2
• This combination achieves approximately 91.5% favorable clinical outcomes by covering typical bacteria and atypical pathogens 1, 2

Option 2: Respiratory fluoroquinolone monotherapy

• Levofloxacin 750 mg orally once daily OR moxifloxacin 400 mg orally once daily for 5–7 days 1, 2, 3
• Fluoroquinolones are active against >98% of S. pneumoniae strains, including penicillin-resistant isolates 1, 2
• Reserve fluoroquinolones for patients with β-lactam allergy or when combination therapy is contraindicated due to FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection) 1, 2

---

Treatment Duration and Monitoring

Standard Duration

• Minimum of 5 days, continuing until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability 1, 2, 3
• Typical total duration for uncomplicated CAP: 5–7 days 1, 2, 3

Extended Duration (Specific Pathogens Only)

• 14–21 days is required only when Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli are isolated 1, 2

Clinical Review and Follow-Up

• Mandatory clinical review at 48 hours (or sooner if symptoms worsen) to assess symptom resolution, oral intake, and treatment response 1, 2
• Routine follow-up at 6 weeks for all patients; obtain chest radiograph only if symptoms persist, physical signs remain, or the patient has high risk for underlying malignancy (e.g., smokers >50 years) 1, 2

---

Critical Pitfalls to Avoid

Do Not Use Macrolide Monotherapy in High-Resistance Areas

• Never use macrolide monotherapy in regions where pneumococcal macrolide resistance exceeds 25% (the situation in most of the United States) 1, 2
• Macrolide monotherapy in patients with comorbidities leads to breakthrough bacteremia and treatment failure 1, 2

Avoid Indiscriminate Fluoroquinolone Use

• Do not use fluoroquinolones as first-line agents in uncomplicated outpatient pneumonia due to FDA safety warnings and rising resistance 1, 2
• Reserve fluoroquinolones for patients with comorbidities, β-lactam allergy, or documented treatment failure 1, 2

Oral Cephalosporins Are Not First-Line

• Oral cephalosporins (cefuroxime, cefpodoxime) should not be used as first-line monotherapy because they show inferior in-vitro activity compared with high-dose amoxicillin, lack coverage of atypical pathogens, and are more costly without demonstrated clinical superiority 1, 2

Switch Antibiotic Class If Recent Use

• If the patient used antibiotics within the past 90 days, select an agent from a different antibiotic class to reduce resistance risk 1, 2

---

Criteria for Treatment Failure and Escalation

Indicators Warranting Hospital Referral

• No clinical improvement by day 2–3 1, 2
• Development of respiratory distress (respiratory rate >30/min, oxygen saturation <92%) 1, 2
• Inability to tolerate oral antibiotics (vomiting, GI dysfunction) 1, 2
• New complications such as pleural effusion or sepsis 1, 2

Escalation Strategy for Outpatient Failure

• If amoxicillin monotherapy fails, add or substitute a macrolide (azithromycin or clarithromycin) to provide atypical pathogen coverage (Mycoplasma, Chlamydophila, Legionella) 1, 2
• If combination therapy (β-lactam + macrolide/doxycycline) fails, switch to a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) 1, 2

---

Prevention and Vaccination

• Offer pneumococcal polysaccharide vaccine to all adults ≥65 years and those with high-risk conditions 1, 2, 3
• Recommend annual influenza vaccination for all patients, especially those with chronic medical illnesses 1, 2, 3
• Provide smoking-cessation counseling to all current smokers 1, 2